Eli Lilly and Co. said it discontinued a trial of an experimental rheumatoid arthritis drug for lack of efficacy.
The trial, in the last stage of three generally required for regulatory approval, is one of three studies of tabalumab in
rheumatoid arthritis, the Indianapolis-based company said Thursday in a prepared statement. The decision wasn’t based
on safety concerns, Lilly said.
The company is still weighing the drug in the two other late-stage studies, and is holding off on enrolling new patients
until more analyses are finished early next year. Those studies are being done in different populations of patients, Lilly
said. The company is still evaluating tabalumab in systemic lupus erythematosus.
“The results of this study were unexpected given the data generated in earlier Phase II clinical studies of tabalumab,”
Eiry Roberts, Lilly’s vice president of autoimmune product development, said in the statement. “We remain committed
to patients with rheumatoid arthritis and lupus and will move rapidly to evaluate the impact of these data on the overall
tabalumab clinical development program.”
Lilly said it expects to take a pretax charge of $20 million to $35 million in the fourth quarter, or about 2 cents a share
after tax. The company’s 2012 forecast is unchanged, it said.
Two other companies reported discouraging trial results for a rheumatoid arthritis drug on Thursday. AstraZeneca PLC and
Rigel Therapeutics Inc. said their drug fostamatinib did not work as well as Abbott Laboratories Inc.'s Humira in a mid-stage
clinical trial. AstraZeneca is running a larger trial of fostamatinib and expects to get results in early 2013.
Rigel's stock plunged 34.6 percent, to $5.51 per share, Thursday on the news.
Humira is the leading rheumatoid arthritis drug by sales, bringing in about $9 billion in annual revenue.
Rheumatoid arthritis is a major area of research for drug companies because it is a chronic condition, meaning patients will
likely take the drugs regularly for a long time. In November, the Food and Drug Administration approved a new treatment for
the disease, Pfizer Inc.'s twice-a-day pill Xeljanz.
Shares of Lilly lost 77 cents, to $48.23 each, on Thursday. AstraZeneca shares fell 2.9 percent, to $47.46, and shares of
Abbott Laboratories lost 69 cents, to $65.32.

















IBJ Conversations
0 Comments
Add Comment